دورية أكاديمية

Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project

التفاصيل البيبلوغرافية
العنوان: Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project
المؤلفون: Souglakos, J. *, Boukovinas, I., Kakolyris, S., Xynogalos, S., Ziras, N., Athanasiadis, A., Androulakis, N., Christopoulou, A., Vaslamatzis, M., Ardavanis, A., Emmanouilides, C., Bompolaki, I., Kourousis, C., Makrantonakis, P., Christofyllakis, C., Athanasiadis, E., Kentepozidis, N., Karampeazis, A., Katopodi, U., Anagnosopoulos, A., Papadopoulos, G., Prinarakis, E., Kalisperi, A., Mavroudis, D., Georgoulias, V.
المصدر: In Annals of Oncology August 2019 30(8):1304-1310
قاعدة البيانات: ScienceDirect
الوصف
تدمد:09237534
DOI:10.1093/annonc/mdz193